{"entity":{"id":"gna13","kind":"target","name":"GNA13","aka":["G protein subunit alpha 13","Guanine nucleotide-binding protein subunit alpha-13","G13","MGC46138"],"tldr":"GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.","summary":"Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1).\n\nCIViC holds 3 clinical evidence items and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Bladder Urothelial Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:4381","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4381"},{"label":"UniProt Q14344","url":"https://www.uniprot.org/uniprotkb/Q14344/entry"},{"label":"NCBI Gene 10672","url":"https://www.ncbi.nlm.nih.gov/gene/10672"},{"label":"Ensembl ENSG00000120063","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120063"}],"tags":["cancer-genes-wave"],"related":["civic","intogen"],"cancers":["urothelial","non-hodgkin-lymphoma","dlbcl","burkitt-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 3 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"GNA13","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:4381","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4381","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q14344","url":"https://www.uniprot.org/uniprotkb/Q14344/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene GNA13","url":"https://civicdb.org/features/8516","note":"3 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen GNA13","url":"https://www.intogen.org/search?gene=GNA13","note":"driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"few-types","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA GNA13: RNA tissue enhanced (bone marrow 136 nTPM); high antibody staining in 11 normal tissues; highest cancer staining thyroid cancer (1 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q14344","url":"https://www.uniprot.org/uniprotkb/Q14344/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene GNA13","url":"https://civicdb.org/features/8516","note":"3 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma, Burkitt Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen GNA13","url":"https://www.intogen.org/search?gene=GNA13","note":"driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas GNA13 tissue","url":"https://www.proteinatlas.org/ENSG00000120063-GNA13/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000120063 associations","url":"https://platform.opentargets.org/target/ENSG00000120063/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:4381","ensembl":"ENSG00000120063","uniprot":"Q14344","entrez":"10672","firstDescribed":1995,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Kabouridis P.S. et al, Mol. Cell. Biochem, 1995, \"Expression of GTP-binding protein alpha subunits in human thymocytes\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7791744/","biology":"Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signalling systems. Activates effector molecule RhoA by binding and activating RhoGEFs (ARHGEF1/p115RhoGEF, ARHGEF11/PDZ-RhoGEF and ARHGEF12/LARG). GNA13-dependent Rho signalling subsequently regulates transcription factor AP-1 (activating protein-1). Promotes tumour cell invasion and metastasis by activating RhoA/ROCK signalling pathway. Inhibits CDH1-mediated cell adhesion in a process independent from Rho activation. In lymphoid follicles, transmits P2RY8- and S1PR2-dependent signals that lead to inhibition of germinal centre (GC) B cell growth and migration outside the GC niche. Location: Cell membrane; Melanosome; Cytoplasm; Nucleus (UniProt). Locus 17q24.1 (HGNC).","whereFound":["Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)","Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM)","Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (DLBCLNOS)","Burkitt lymphoma: CIViC evidence names this disease"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/gna13/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}